Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
aspirin + clopidogrel + cilostazol (Xuanwu Hospital)
- Development stage
- Unknown
- Lead developer
- Xuanwu Hospital
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
This entry refers to an individualized antithrombotic treatment regimen guided by Thromboelastography (TEG) for the secondary prevention of ischemic stroke and cerebrovascular disease. Developed and studied at Xuanwu Hospital in Beijing, the protocol involves monitoring platelet reactivity using TEG to adjust the selection and dosage of antiplatelet agents, specifically aspirin, clopidogrel, and cilostazol. The goal is to achieve 'desirable' TEG parameters to optimize therapeutic efficacy and minimize the risk of recurrent stroke or bleeding complications. The regimen typically involves switching between or combining these small molecule inhibitors based on the patient's specific coagulation profile as measured by the TEG device.
- Brand names
- BayaspirinPlavixPletal
- Other names
- Individualized Antithrombotic Therapy guided by TEGDesirable TEGUndesirable TEG
02
Targets
P2Y12 (Purinergic P2Y12 receptor)PDE3PGHS-1 (Prostaglandin G/H Synthase 1)
Beyond the preview
Go deeper on aspirin + clopidogrel + cilostazol (Xuanwu Hospital).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on aspirin + clopidogrel + cilostazol (Xuanwu Hospital).